戻る

Capricor Therapeutics faces lawsuit over deramiocel FDA approval statements

  • Capricor Therapeutics faces a class action lawsuit over deramiocel statements.
  • The complaint alleges false statements about deramiocel’s progress toward FDA approval.
  • The lawsuit claims Capricor promoted positive trial results to investors.

Capricor Therapeutics is facing a class action lawsuit alleging it made false statements about deramiocel’s progress toward FDA (U.S. drug regulator) approval. The complaint claims the company misled investors by promoting positive trial results in connection with the drug candidate.

当サイトの情報はAIを用いて生成されており、正確性を保証するものではありません。 参考情報としてご活用ください。
Capricor Therapeutics faces lawsuit over deramiocel FDA approval statements - CoinPost Terminal